World News

Under the agreement, the companies will identify and implement targeted applications of agentic AI, an AI systems designed to perform tasks and execute workflows with varying degrees of autonomy.

Located in Kendall Square, a major biotechnology and life sciences hub, the new centre will operate alongside AstraZeneca’s genomic medicine facility at 100 Binney Street.

Under the agreement, Roche’s Genentech subsidiary will oversee development, regulatory activities, manufacturing and commercialisation across all indications.

IntraBio will become a wholly owned subsidiary of Shionogi Inc., the Japanese group’s US-based subsidiary in New Jersey.

The Bristol site’s focus on GMP small molecules adds to this portfolio, extending the company’s capacity to supply materials used in the development and production of advanced therapies.

Bamberg brings more than 20 years of international experience in regulated manufacturing, with expertise spanning medical devices, combination products and pharmaceutical production.

The agreement was signed at the Precision Health Partnerships in Singapore event and witnessed by Ong Ye Kung, Singapore’s Minister for Health and Coordinating Minister for Social Policies.

The planned campus at the New Albany International Business Park will use a flexible, modular design combining drug substance and drug product manufacturing with digital and automation technologies.

The NMPA approved VELSIPITY in February 2026 for adults with moderately to severely active ulcerative colitis (UC) who had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent.

It is now integrating those businesses under Asahi Kasei Therapeutics, the name of its existing Japanese pharmaceutical unit.